Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2007

View Archived Issues

Prous Sciences publishes new Integrity Disease Briefing on myasthenia gravis

Novel anticancer agents disclosed in recent patents

Recent patents disclose novel therapeutic agents for inflammatory disorders

Recent Merck patent imparts novel antiobesity agents

Boehringer Ingelheim to evaluate Aptivus in diverse patient population

Novel treatment options for autoimmune disorders described in recent patents

Inhibition of aP2: a novel therapeutic strategy in treating diabetes and atherosclerosis

Apo2L/TRAIL in patients with advanced tumors

NeuroSearch's latest pipeline progress and status

Phase III findings show benefit of AMG-0001 in critical limb ischemia

Canadian approval for Elaprase for Hunter's syndrome

Enrollment completed in phase I study of SL-017 in actinic keratosis

NicOx takes precautionary measures on NCX-4016 program

Novo Nordisk studies GlycoPEGylated factor VIIa in phase I trial

Highlights from the Alzheimer's Association International Conference on Prevention of Dementia

Meda acquires sotirimod from 3M

Diamyd Medical invalidates diabetes study

Novel multi-target tyrosine kinase inhibitor profiled at LEO

Solvay seeks new indications for AndroGel

Japanese launch for Abilify Tablet 12 mg

Nuvigil approved to treat excessive sleepiness

NuvaRing approved in additional E.U. countries

First E.U. launches for Advagraf in U.K. and Germany

Bazedoxifene/conjugated estrogens improves BMD in postmenopausal women

Japanese launch planned for Pletaal Powder 20%

Expanded access program opens for Kuvan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...